Health (PRISME)

  • Presentation
  • Activities
  • Members
  • Publications

The PRISME team is composed of physicists, biochemists, biologists and radiotherapists. We specialize in multidisciplinary research aimed at developing, optimizing and controlling innovative radiotherapies, whether it be hadrontherapy or therapies using radioactive ion-emitting elements or nanoparticles. These radiotherapies aim to improve the treatment of certain cancers by increasing the effect of ionizing radiation in the tumor while minimizing its harmful effects on healthy tissues.

Our multidisciplinary approach aims to quantify, understand and predict the effect of ionizing radiation on living organisms from processes induced at extremely short times (attosecond) at small scales (atomic nucleus) to long-term consequences (years) at the patient level.
We therefore design and carry out irradiation experiments on targets ranging from molecules or cells to small animals and patient samples (tumor, blood). These experiments feed an important part of our activity which consists in modeling the effects of radiation on living organisms.

One of the innovative techniques of radiotherapy is hadrontherapy, which is to send
an ion beam on the tumors to destroy them. We are working, in particular using simulations, data processing and predictions, to improve these systems by having on-line control over irradiation using dedicated detectors. These tools also have applications in imaging.

The activities can be divided into three research areas:

Axis 1 aims to develop simulations and detectors to control patient irradiation by detecting the particles emitted during hadrontherapy treatment. These developments also offer application prospects in the field of diagnostic imaging.

Axis 2 focuses on the development of multi-scale models and simulations to describe and predict the physical, chemical and biological processes induced by irradiation. It also develops irradiation and dosimetric control means for the measurement of radiobiological effects.

Axis 3 quantifies by experiment the effects induced by irradiation with molecular, cellular, multicellular, in-vitro or in-vivo systems. It focuses on the specificities of innovative radiotherapies and the personalization of care.

PERMANENTS:

NON-PERMANENTS:

- DOCTORANTS / DOCTORAL STUDENTS:

- CHERCHEURS NON-PERMANENTS / NON-PERMANENT RESEARCHERS:
546 documents

  • Claire Rodriguez-Lafrasse, Yannick Saintigny, François Chevalier, Myriam Bernaudin, Carine Laurent, et al.. Translational research in radiobiology in the framework of France HADRON national collaboration. Translational Cancer Research, 2017, 6 (S5), pp.S795-S806. ⟨10.21037/tcr.2017.06.33⟩. ⟨hal-01610093⟩
  • Michael Beuve. Biophysics Modeling to Optimize Ion Beam Cancer Therapy. Nanoscale Insights into Ion-Beam Cancer Therapy, Springer International Publishing Switzerland, pp.435-465, 2017, ⟨10.1007/978-3-319-43030-0_13⟩. ⟨hal-01458953⟩
  • Micaela Cunha, Etienne Testa, Michael Beuve, Jacques Balosso, Abdulhamid Chaikh. Considerations on the miniaturization of detectors for in vivo dosimetry in radiotherapy: A Monte Carlo study. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, 2017, 399, pp.20-27. ⟨10.1016/j.nimb.2017.03.078⟩. ⟨hal-01582804⟩
  • Mattia Fontana, Denis Dauvergne, Jean Michel Létang, Jean-Luc Ley, Etienne Testa. Compton camera study for high efficiency SPECT and benchmark with Anger system. Physics in Medicine and Biology, 2017, 62, pp.8794-8812. ⟨10.1088/1361-6560/aa926a⟩. ⟨hal-01685468⟩
  • C. Monini, É. Testa, M. Beuve. NanOx Predictions of Cell Survival Probabilities for Three Cell Lines. Acta Phys.Polon.B, 2017, 48 (10), pp.1653. ⟨10.5506/APhysPolB.48.1653⟩. ⟨hal-01719459⟩
  • Micaela Cunha, Caterina Monini, Etienne Testa, Michael Beuve. NanOx, a new model to predict cell survival in the context of particle therapy. Physics in Medicine and Biology, 2017, 62 (4), pp.1248-1268. ⟨10.1088/1361-6560/aa54c9⟩. ⟨hal-01446509⟩
  • Wook-Geun Shin, Mauro Testa, Hak Soo Kim, Jong Hwi Jeong, Se Byeong Lee, et al.. Independent dose verification system with Monte Carlo simulations using TOPAS for passive scattering proton therapy at the National Cancer Center in Korea. Physics in Medicine and Biology, 2017, 62 (19), pp.7598-7616. ⟨10.1088/1361-6560/aa8663⟩. ⟨hal-01763848⟩
  • Jean-Baptiste Guy, Sophie Espenel, Alexis Vallard, Priscillia Battiston-Montagne, Anne-Sophie Wozny, et al.. Evaluation of the Cell Invasion and Migration Process: A Comparison of the Video Microscope-based Scratch Wound Assay and the Boyden Chamber Assay. Journal of visualized experiments : JoVE, 2017, 129, pp.e56337. ⟨10.3791/56337⟩. ⟨hal-01690773⟩
  • Benoîte Méry, Jean-Baptiste Guy, Alexis Vallard, Sophie Espenel, Dominique Ardail, et al.. In Vitro Cell Death Determination for Drug Discovery: A Landscape Review of Real Issues. Journal of Cell Death, 2017, 10, ⟨10.1177/1179670717691251⟩. ⟨hal-01610108⟩
  • Claire Rodriguez-Lafrasse. Why Carbon Ions Better Cure Radioresistant Cancers: the Cellular and Molecular Visions of the Radiobiologist. 2016. ⟨hal-01486883⟩

Powered by HAL logo